725
Participants
Start Date
July 6, 2015
Primary Completion Date
March 2, 2017
Study Completion Date
September 30, 2020
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
DRV/COBI FDC
A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
FTC/TDF FDC
A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
D/C/F/TAF FDC - Matching Placebo
Matching placebo of D/C/F/TAF FDC will be administered once daily.
FTC/TDF FDC Matching Placebo
Matching placebo of FTC/TDF FDC will be administered once daily.
DRV/COBI FDC Matching Placebo
Matching placebo of DRV/COBI FDC will be administered once daily.
Birmingham
Phoenix
Bakersfield
Long Beach
Los Angeles
North Hollywood
San Francisco
Washington D.C.
Ft. Pierce
Miami
Orlando
West Palm Beach
Savannah
Boston
Springfield
Berkley
Minneapolis
St Louis
Hillsborough
Newark
Somers Point
Santa Fe
Manhasset
Chapel Hill
Winston-Salem
Cincinnati
Fort Worth
Houston
Seattle
Antwerp
Brussels
Ghent
Toronto
Montreal
Clamart
Le Kremlin-Bicêtre
Lyon
Marseille
Montpellier
Nantes
Paris
Strasbourg
Tourcoing
Berlin
Bonn
Cologne
Essen
Frankfurt
Freiburg im Breisgau
Hamburg
Hanover
München
Bydgoszcz
Chorzów
Krakow
Lodz
Szczecin
Warsaw
Wroclaw
San Juan
Krasnodar
Oryol
Saint Petersburg
Saratov
Smolensk
Tolyatti
Voronezh
Yekaterinburg
Alicante
Badalona
Barcelona
Córdoba
Elche
Madrid
Santiago de Compostela
Seville
Valencia
Brighton
Bristol
London
Janssen Sciences Ireland UC
INDUSTRY